Results 91 to 100 of about 4,841,252 (345)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Comprehensive analysis of peripheral dose in electron beam therapy with a Varian TrueBeam Linac

Radiation Medicine and Protection
Objective: To investigate the characteristics of peripheral doses outside electron-beam applicators in Varian TrueBeam linacs. Method: Peripheral doses outside the electron applicator were measured for 6-, 9- and 12-MeV beams at the maximum dose depth ...
Kapil Dev Maharaj, Mahsheed Sabet, Joshua Dass, Mounir Ibrahim, Talat Mahmood, Pejman Rowshanfarzad   +5 more
doaj   +1 more source

CALCIUM CHANNEL BLOCKADE AND FUNCTIONAL MICROCIRCULATION CHANGES IN HYPERTENSIVE PATIENTS WITH DIFFERENT INDIVIDUAL AND TYPOLOGICAL CHARACTERISTICS

Кардиоваскулярная терапия и профилактика, 2013
Aim. To identify individual and typological functional features of peripheral blood flow and assess microcirculation (MC) dynamics after a single-dose administration of nifedipine in patients with arterial hypertension (AH).Material and methods.
A. P. Vasiliev, N. N. Streltsova, E. A. Shumeiko   +2 more
doaj   +1 more source

Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population

The Pan African Medical Journal, 2020
The most important limits of oxaliplatin treatment is its peripheral neurotoxicity. The aim of our study was to evaluate the oxaliplatin-induced peripheral neuropathy, its impact on treatment and its management.
Aref Zribi, Sonia Ben Nasr, Syrine Hamdi, Jihen Ayari, Sana Fendri, Mehdi Balti, Abderrazek Haddaoui   +6 more
doaj   +1 more source

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor [PDF]

, 2013
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
A Dar, A D’Souza, A Foudi, A Nagler, A Peled, AM Greenbaum, AW Roberts, B Nervi, CC Bleul, CL Semerad, D Obrecht, DE Harrison, F Ferraro, F Liu, GA Velders, GL Uy, H Balaguer, H Bonig, H Bonig, H Bonig, H Bonig, H Bonig, HE Broxmeyer, IG Winkler, JP Levesque, JP Levesque, K Balabanian, MA Pulsipher, MA Ryan, MJ Christopher, MM Mueller, MP Rettig, MZ Ratajczak, N Amariglio, P Anderlini, P Anderlini, P Anderlini, S Akizuki, SJ DeMarco, SJ Szilvassy, SM Devine, SP Fricker, T Lapidot, TA Lane, V Saini, WC Liles, Y Katayama, Y Takamatsu   +47 more
core   +1 more source

Peripheral dose distributions for a linear accelerator equipped with a secondary multileaf collimator and universal wedge

Journal of Applied Clinical Medical Physics, 2002
The American Association of Physicists in Medicine Task Group 36 (AAPM TG‐36) data can be used to estimate peripheral dose (PD) distributions outside the primary radiation field.
S. Mutic, J. Esthappan, E. Klein
semanticscholar   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA)

Arthritis Research & Therapy
Background CXC chemokine CXCL12 is involved in the pathological development of rheumatoid arthritis (RA) through abnormal migration of peripheral immune cells in the joint.
Lei Ding, Daniel H. Park, Bo Gao, Lingyuan Wu, Meizhang Li, Haitham Abedelhakim, Ming Zhang   +6 more
doaj   +1 more source

Quantitative detection of targeted neurotransmitters in dorsal root ganglia in rats with chronic peripheral neurotoxicity caused by oxaliplatin

Di-san junyi daxue xuebao, 2020
Objective To observe the effects of oxaliplatin on the concentration of neurotransmitters in dorsal root ganglia in a rat model of chronic peripheral neurotoxicity. Methods A total of 24 male SD rats (SPF grade) were randomly divided into model group and
ZHENG Wenling, CHEN Yanrong, OU Juanjuan, LIANG Houjie   +3 more
doaj   +1 more source

Influence of FK 506 (tacrolimus) on circulating CD4 ⁺ t cells expressing cd25 and cd45ra antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial [PDF]

, 1994
We have taken the opportunity of a clinical trial of the potential efficacy and safety of FK 506 (tacrolimus) in chronic progressive multiple sclerosis (MS) to examine the influence of this potent new immunosuppressant on circulating T-lymphocytes in an ...
A. W. Thomson, Abu-Elmagd K., B. Eidelman, B. Lemster, Collett D, Eidelman B H., Ellison G W., Emry P., Fung J J., H. R. Rilo, Hafler D A., Hafler D A., Hauser S L., Hintzen R Q., Hofman F M., J. J. Fung, J. Woo, Japanese FK, K. Abu-Elmagd, Kino T., Kurtzke J F, L. L. Huang, Lebranchu Y., Lemster B., Lemster B., McCauley J., McMichael J., Mochizuki M., Mortimoto C, N. Johnson, P. B. Carroll, R. Russell-Hall, Rose L M., Starzl T E., T. E. Starzl, Tamura K., The Multiple Sclerosis Study Group, Thomson A V., Thomson A W, Thomson A W., Thomson A W., Thomson A W., Tocci M J., W. Irish, Woo J., Woo J., Zeevi A.   +46 more
core   +1 more source